NO2699580T3 - - Google Patents

Info

Publication number
NO2699580T3
NO2699580T3 NO12774761A NO12774761A NO2699580T3 NO 2699580 T3 NO2699580 T3 NO 2699580T3 NO 12774761 A NO12774761 A NO 12774761A NO 12774761 A NO12774761 A NO 12774761A NO 2699580 T3 NO2699580 T3 NO 2699580T3
Authority
NO
Norway
Application number
NO12774761A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2699580(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2699580T3 publication Critical patent/NO2699580T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Epoxy Compounds (AREA)
NO12774761A 2014-01-24 2012-04-15 NO2699580T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24

Publications (1)

Publication Number Publication Date
NO2699580T3 true NO2699580T3 (de) 2018-02-24

Family

ID=52432834

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12774761A NO2699580T3 (de) 2014-01-24 2012-04-15

Country Status (37)

Country Link
US (18) US9522894B2 (de)
EP (3) EP3744714A1 (de)
JP (5) JP6469711B2 (de)
KR (1) KR102417684B1 (de)
CN (2) CN110483492B (de)
AP (1) AP2016009322A0 (de)
AR (1) AR099177A1 (de)
AU (4) AU2015208932C1 (de)
BR (1) BR112016016224B1 (de)
CA (1) CA2935625C (de)
CL (1) CL2016001889A1 (de)
CR (1) CR20160327A (de)
CY (2) CY1120049T1 (de)
DK (2) DK3097086T3 (de)
DO (1) DOP2016000175A (de)
EA (1) EA032794B1 (de)
ES (2) ES2658516T3 (de)
HK (2) HK1225730B (de)
HR (2) HRP20180116T1 (de)
HU (2) HUE038274T2 (de)
IL (3) IL246614B (de)
LT (2) LT3097086T (de)
MX (1) MX368840B (de)
MY (1) MY194850A (de)
NO (1) NO2699580T3 (de)
NZ (2) NZ722063A (de)
PE (1) PE20161218A1 (de)
PH (1) PH12016501439B1 (de)
PL (2) PL3323814T3 (de)
PT (2) PT3323814T (de)
RS (2) RS60639B1 (de)
SG (2) SG11201606052TA (de)
SI (2) SI3323814T1 (de)
TW (1) TWI690517B (de)
UY (1) UY35963A (de)
WO (1) WO2015110826A1 (de)
ZA (2) ZA201605856B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (de) 2014-01-24 2018-02-24
KR20190035781A (ko) * 2016-07-29 2019-04-03 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
CA3091707A1 (en) 2018-03-01 2019-09-06 Astrazeneca Ab Pharmaceutical compositions comprising (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CA3106270A1 (en) * 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
CA3150236A1 (en) * 2019-10-23 2021-04-29 Young Il Choi COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CHRONIC OBSTRUCTIVE BRONCHO-PNEUMOPATHIES (COPD)
AU2021314104A1 (en) * 2020-07-20 2023-01-19 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
EP4129989B1 (de) * 2020-08-26 2024-10-02 Haisco Pharmaceuticals Pte. Ltd. Nitrilderivat als dipeptidylpeptidase-1-hemmer und verwendung davon
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
WO2022117059A1 (zh) 2020-12-04 2022-06-09 瑞石生物医药有限公司 组织蛋白酶c小分子抑制剂及其医药用途
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
EP4289827A1 (de) * 2021-02-05 2023-12-13 Medshine Discovery Inc. 1,4-oxazepane enthaltende kondensierte ringderivate
CA3236069A1 (en) * 2021-10-29 2023-05-04 Ariel Teper Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
WO2023134656A1 (zh) * 2022-01-11 2023-07-20 上海壹典医药科技开发有限公司 一种肽基腈类化合物及其应用
IL314769A (en) * 2022-02-16 2024-10-01 Insmed Incorporated Seratin N-(1-cyano-2-phenylethyl)-4,1-oxazapan-2-carboxamides for the treatment of hidradenitis suppurativa
IL314855A (en) * 2022-02-22 2024-10-01 Haisco Pharmaceuticals Pte Ltd Preparation method of a heterocyclic compound containing nitrogen
CN118660873A (zh) * 2022-02-22 2024-09-17 西藏海思科制药有限公司 二肽基肽酶抑制剂化合物的盐及晶型
WO2023160579A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 一种二肽基肽酶1抑制剂多晶型物及其制备方法和用途
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
TW202404961A (zh) * 2022-06-07 2024-02-01 大陸商瑞石生物醫藥有限公司 苯并［ｃ］色滿化合物的可藥用鹽、其多晶型及用途
WO2023236879A1 (zh) * 2022-06-07 2023-12-14 瑞石生物医药有限公司 苯并[c]色满化合物的多晶型及其制备方法和用途
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
WO2024148308A1 (en) * 2023-01-06 2024-07-11 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
WO2024193695A1 (zh) * 2023-03-23 2024-09-26 西藏海思科制药有限公司 一种二肽基肽酶小分子抑制剂的药物组合物

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
WO2002020804A1 (en) 2000-09-08 2002-03-14 Prozymex A/S Rat cathepsin, dipeptidyl peptidase i (dppi): crystal structure, inhibitors and its uses
EP1217000A1 (de) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Faktor Xa und Faktor VIIa Inhibitoren
CN1315806C (zh) 2001-12-04 2007-05-16 霍夫曼·拉罗奇有限公司 取代的2－氨基－环烷烃甲酰胺和它们作为半胱氨酸蛋白酶抑制剂的用途
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
EP2258365B1 (de) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Verwendung von organischen verbindungen zur immunstärkung
US20070155803A1 (en) 2003-05-30 2007-07-05 Prozymex A/S Protease inhibitors
JP2006527704A (ja) * 2003-06-18 2006-12-07 プロザイメックス・アクティーゼルスカブ プロテアーゼ阻害剤
PT1732949E (pt) 2004-04-07 2010-03-23 Univ Minnesota Métodos de tratamento da dor associada ao cancro ósseo através da administração de um antagonista do factor de crescimento nervoso
EP1745292A2 (de) 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnositka und therapeutika für mit dipeptidyl-peptidase 1 (dpp1) assoziierten krankheiten
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
EP1916994B1 (de) 2004-06-29 2013-12-11 Takeda Pharma A/S Herstellung einer pharmazeutischen zusammensetzung mit schneller freisetzung aus wasserunlöslichen arzneimitteln und mit dem erfindungsgemässen verfahren erhaltene pharmazeutische zusammensetzungen
WO2006020145A2 (en) 2004-07-19 2006-02-23 The Johns Hopkins University Flt3 inhibitors for immune suppression
EP1853250B1 (de) 2005-02-18 2011-11-02 Abraxis BioScience, LLC Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie
JP2009500347A (ja) 2005-06-30 2009-01-08 アムジエン・インコーポレーテツド ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用
CA2680312A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
CN101873851A (zh) 2007-09-25 2010-10-27 诺瓦提斯公司 用气雾化药物如万古霉素治疗肺部疾病
WO2009074829A1 (en) * 2007-12-12 2009-06-18 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
MX2011006108A (es) 2008-12-08 2011-11-18 Vm Pharma Llc Composiciones de inhibidores de los receptores tirosina quinasa.
WO2010114405A2 (en) 2009-04-01 2010-10-07 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
BRPI1015540A2 (pt) * 2009-05-07 2019-09-24 Astrazeneca Ab ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
CN106943403A (zh) 2010-04-07 2017-07-14 弗特克斯药品有限公司 药物组合物和其给药方法
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
SG192669A1 (en) 2011-02-11 2013-09-30 Glaxosmithkline Ip Dev Ltd Cathepsin c inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
AU2013224421B2 (en) 2012-02-21 2017-03-02 Merck Patent Gmbh 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
CN104284895B (zh) 2012-04-17 2016-08-31 安斯泰来制药株式会社 含氮双环式芳香族杂环化合物
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (de) 2013-03-07 2014-09-10 Universitätsspital Basel Verfahren zum Nachweis einer entzündlichen Störung
EP2970228B1 (de) 2013-03-14 2017-05-10 Boehringer Ingelheim International GmbH Substituierte 2-aza-bicyclo[2.2.1]heptan-3-carboxylsäure (cyan-methyl)-amid-hemmstoffen von cathepsin c
US8889708B2 (en) 2013-03-14 2014-11-18 Boehringer Ingelheim International Gmbh Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
WO2014140091A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
DK2970283T3 (da) 2013-03-14 2021-01-25 Boehringer Ingelheim Int Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
US10670594B2 (en) 2013-08-22 2020-06-02 Emory University Devices and methods related to airway inflammation
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
AU2014317048B2 (en) 2013-09-09 2018-05-10 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (de) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
TW201622721A (zh) 2014-04-10 2016-07-01 諾華公司 Ｓ１ｐ調節劑之立即釋放劑量療法
EP3466432B1 (de) 2014-05-15 2020-07-08 Insmed Incorporated Verfahren zur behandlung von pulmonaler mykobakterieller nichttuberkuloseinfektionen
EP3149192B1 (de) 2014-05-30 2019-01-02 Versitech Limited Verfahren und zusammensetzungen zur verwendung von neutrophiler elastase und proteinase 3 als diagnostische biomarker
WO2016016242A1 (en) 2014-08-01 2016-02-04 Boehringer Ingelheim International Gmbh Substituted oxetanes and their use as inhibitors of cathepsin c
SI3191487T1 (sl) 2014-09-12 2019-12-31 Boehringer Ingelheim International Gmbh Spirociklični inhibitorji katepsina C
EP3218372B1 (de) 2014-11-14 2020-05-20 Boehringer Ingelheim International GmbH Morpholin- und 1,4-oxazepanamide als somatostatinrezeptor-subtyp-4(sstr4)-agonisten
US10479781B2 (en) 2015-03-05 2019-11-19 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
KR20190035781A (ko) 2016-07-29 2019-04-03 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
CA3091707A1 (en) 2018-03-01 2019-09-06 Astrazeneca Ab Pharmaceutical compositions comprising (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CA3106270A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
KR20220022115A (ko) 2019-04-17 2022-02-24 아조라 테라퓨틱스 인코포레이티드 염증성 피부 질환을 치료하기 위한 국소 조성물 및 방법
MX2021014742A (es) 2019-06-05 2022-02-11 Univ Emory Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
KR20240004691A (ko) 2021-04-29 2024-01-11 인스메드 인코포레이티드 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
CA3236069A1 (en) 2021-10-29 2023-05-04 Ariel Teper Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
IL314769A (en) 2022-02-16 2024-10-01 Insmed Incorporated Seratin N-(1-cyano-2-phenylethyl)-4,1-oxazapan-2-carboxamides for the treatment of hidradenitis suppurativa

Also Published As

Publication number Publication date
US11655221B2 (en) 2023-05-23
PL3097086T3 (pl) 2018-04-30
MY194850A (en) 2022-12-19
PE20161218A1 (es) 2016-11-27
US20150210655A1 (en) 2015-07-30
HK1255870A1 (zh) 2019-08-30
LT3323814T (lt) 2020-10-26
CN105980367B (zh) 2019-08-23
US20230115170A1 (en) 2023-04-13
ZA201800431B (en) 2019-09-25
US20200247765A1 (en) 2020-08-06
JP2023156479A (ja) 2023-10-24
ZA201605856B (en) 2020-02-26
EP3097086B1 (de) 2017-12-13
PH12016501439A1 (en) 2017-02-06
CA2935625C (en) 2022-10-18
US11673872B2 (en) 2023-06-13
AU2015208932A8 (en) 2017-03-09
AU2019202675A1 (en) 2019-05-16
AU2019202675B2 (en) 2020-05-28
DK3097086T3 (en) 2018-02-05
JP7157791B2 (ja) 2022-10-20
US20240336582A1 (en) 2024-10-10
BR112016016224B1 (pt) 2023-02-23
US20210238152A1 (en) 2021-08-05
US20230250071A1 (en) 2023-08-10
CR20160327A (es) 2016-10-20
AU2015208932C1 (en) 2017-05-25
AU2018202956A1 (en) 2018-05-17
AU2015208932A1 (en) 2016-07-28
US20170057938A1 (en) 2017-03-02
US12054465B2 (en) 2024-08-06
SG10201701056QA (en) 2017-03-30
KR20160111470A (ko) 2016-09-26
EP3323814A1 (de) 2018-05-23
HRP20180116T1 (hr) 2018-03-23
US20180251436A1 (en) 2018-09-06
US20240132455A1 (en) 2024-04-25
US11667615B2 (en) 2023-06-06
HRP20201147T1 (hr) 2020-12-11
US20230025351A1 (en) 2023-01-26
DK3323814T3 (da) 2020-08-03
US9522894B2 (en) 2016-12-20
JP2017503832A (ja) 2017-02-02
NZ734768A (en) 2022-09-30
SI3097086T1 (en) 2018-04-30
JP6469711B2 (ja) 2019-02-13
AU2017200338B2 (en) 2018-03-01
AU2015208932B2 (en) 2017-02-16
HK1225730B (zh) 2017-09-15
EA201691375A1 (ru) 2017-01-30
ES2808060T3 (es) 2021-02-25
JP7336563B2 (ja) 2023-08-31
AU2017200338A1 (en) 2017-02-02
IL265611A (en) 2019-05-30
DOP2016000175A (es) 2016-08-15
JP2021046423A (ja) 2021-03-25
AP2016009322A0 (en) 2016-07-31
US10669245B2 (en) 2020-06-02
PT3323814T (pt) 2020-08-05
CY1120049T1 (el) 2018-12-12
AU2015208932B8 (en) 2017-03-09
LT3097086T (lt) 2018-02-26
US11655222B2 (en) 2023-05-23
US20230085620A1 (en) 2023-03-23
US10287258B2 (en) 2019-05-14
US20200017455A1 (en) 2020-01-16
SG11201606052TA (en) 2016-08-30
CL2016001889A1 (es) 2016-12-09
CN105980367A (zh) 2016-09-28
MX2016009349A (es) 2016-10-13
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
AU2018202956B2 (en) 2019-05-09
JP2022096662A (ja) 2022-06-29
CY1123391T1 (el) 2021-12-31
AR099177A1 (es) 2016-07-06
PL3323814T3 (pl) 2020-10-19
EA032794B1 (ru) 2019-07-31
US9815805B2 (en) 2017-11-14
RS60639B1 (sr) 2020-09-30
US20230116721A1 (en) 2023-04-13
US20230278969A1 (en) 2023-09-07
ES2658516T3 (es) 2018-03-12
US11117874B2 (en) 2021-09-14
TW201612167A (en) 2016-04-01
CN110483492B (zh) 2023-07-21
CA2935625A1 (en) 2015-07-30
TWI690517B (zh) 2020-04-11
EP3097086A1 (de) 2016-11-30
US20230062646A1 (en) 2023-03-02
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
JP6804570B2 (ja) 2020-12-23
NZ722063A (en) 2017-09-29
JP2019070029A (ja) 2019-05-09
US11680049B2 (en) 2023-06-20
US11655223B2 (en) 2023-05-23
IL252836A0 (en) 2017-08-31
HUE052421T2 (hu) 2021-04-28
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
US20230028726A1 (en) 2023-01-26
US20230033573A1 (en) 2023-02-02
SI3323814T1 (sl) 2020-10-30
US11814359B2 (en) 2023-11-14
US11673871B2 (en) 2023-06-13
WO2015110826A1 (en) 2015-07-30
US11655224B2 (en) 2023-05-23
PH12016501439B1 (en) 2017-02-06
US20230069044A1 (en) 2023-03-02
CN110483492A (zh) 2019-11-22
MX368840B (es) 2019-10-18
EP3323814B1 (de) 2020-05-13
BR112016016224A2 (de) 2017-08-08
KR102417684B1 (ko) 2022-07-05
EP3744714A1 (de) 2020-12-02

Similar Documents

Publication Publication Date Title
BR112014021090A2 (de)
BR112014017635A2 (de)
BR112014017614A2 (de)
BR112014017625A2 (de)
BR112014017592A2 (de)
AR092201A1 (de)
BR112014017638A2 (de)
NO2699580T3 (de)
BR112014017607A2 (de)
BR112014020246A2 (de)
BR112014019371A2 (de)
BR112013027865A2 (de)
BR112014017634A2 (de)
BR112014017609A2 (de)
BR112014017644A2 (de)
BR112014017588A2 (de)
BR112014017618A2 (de)
BR112014013184A8 (de)
BR112014017630A2 (de)
BR112014017621A2 (de)
BR112014017622A2 (de)
BR112014017627A2 (de)
BR112014017623A2 (de)
BR112014017641A2 (de)
BR112014019870A2 (de)